Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an announcement.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the nine months ending September 30, 2025. The company saw an increase in revenue and net profit compared to the previous year, with revenue reaching RMB 4.77 billion and net profit at RMB 1.28 billion. Despite a decrease in total assets, the company experienced a positive net increase in cash and cash equivalents, indicating improved liquidity. Stakeholders are advised to exercise caution as the financials are unaudited and may require adjustments.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a company involved in the pharmaceutical industry, with a focus on producing and distributing pharmaceutical products. It holds a significant stake in Dong-E-E-Jiao, a company listed on the Shenzhen Stock Exchange, which specializes in producing traditional Chinese medicine products.
Average Trading Volume: 16,744,630
Technical Sentiment Signal: Sell
Current Market Cap: HK$30.6B
Learn more about 3320 stock on TipRanks’ Stock Analysis page.